News
ALKS
33.75
+1.17%
0.39
Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative?
Simply Wall St · 4h ago
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE)
TipRanks · 20h ago
Weekly Report: what happened at ALKS last week (0406-0410)?
Weekly Report · 21h ago
Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Alkermes (ALKS)
TipRanks · 4d ago
Alkermes Price Target Raised to $36.00/Share From $34.00 by B of A Securities
Dow Jones · 4d ago
Alkermes Is Maintained at Neutral by B of A Securities
Dow Jones · 4d ago
B of A Securities Maintains Neutral on Alkermes, Raises Price Target to $36
Benzinga · 4d ago
Alkermes price target raised to $36 from $34 at BofA
TipRanks · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)
TipRanks · 4d ago
Alkermes EVP, CLO David Joseph Gaffin disposes of USD 70,309 in shares
Reuters · 04/06 23:57
Weekly Report: what happened at ALKS last week (0330-0403)?
Weekly Report · 04/06 10:22
Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet?
Simply Wall St · 04/06 09:19
Assessing Alkermes (ALKS) Valuation After Recent Share Price Momentum
Simply Wall St · 04/03 10:39
Mizuho Securities Sticks to Their Buy Rating for Alkermes (ALKS)
TipRanks · 04/02 00:15
Alkermes EVP R&D, CMO Craig Hopkinson disposes of shares worth $0.3 million
Reuters · 04/01 22:59
Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside
Simply Wall St · 04/01 21:21
Alkermes management to meet with Piper Sandler
TipRanks · 04/01 20:50
TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)
TipRanks · 04/01 20:15
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Reuters · 04/01 16:14
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Reuters · 04/01 13:14
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.